ArticleJournal of immunology research2022
The Dectin-1 Receptor Signaling Pathway Mediates the Remyelination Effect of Lentinan through Suppression of Neuroinflammation and Conversion of Microglia.
Article in Journal of immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Recent Trends in Tissue Engineering Strategies for Uterine Endometrial Regeneration: a Systematic Review.Reproductive sciences (Thousand Oaks, Calif.) · 2026Pooled it
- Potential of Hair Follicle Stem Cell-Derived Exosomes Carrying miR-181a-5p to Promote the Telogen-to-Anagen Stage.Aesthetic plastic surgery · 2026Article
- Small Animal Models for Translational Research in Atrial Fibrillation.Journal of cardiovascular translational research · 2026Review
- Natural Medicines Modulating Tumor Perineural Invasion: Regulatory Mechanisms and Therapeutic Potential.Drug design, development and therapy · 2026Review
- Fungal Polysaccharides as Modulators of Molecular Pathways in Liver Health.Molecules (Basel, Switzerland) · 2025Review
- Phytochemical Nanoparticles for the Treatment of Neurological Disorders.Phytochemical analysis : PCA · 2025Review
- Unlocking therapeutic potential in traumatic brain injury: exploring microenvironmental targets, signaling pathways and translational hurdles.Inflammopharmacology · 2025Review
- Targeting the Dectin-1 Receptor in Neuroinflammation: Therapeutic Implications for Neuropsychiatric Disorders.ACS chemical neuroscience · 2025Review
- Analysis of research trends and hotspots in the primary treatment of end-stage renal disease.International urology and nephrology · 2025Review
- Mechanisms of action of fungal polysaccharides and their therapeutic effect.European journal of clinical nutrition · 2025Review
- Decoding Microglial Polarization and Metabolic Reprogramming in Neurodegenerative Diseases: Implications for Disease Progression and Therapy.Aging and disease · 2025Review
- Immunomodulatory actions of tonifying polysaccharides: pharmacological effects, mechanisms and therapeutic applications.Frontiers in immunology · 2025Review
- A Contrastive-Learning-Based Deep Neural Network for Cancer Subtyping by Integrating Multi-Omics Data.Interdisciplinary sciences, computational life sciences · 2024Article
- IL-17 and IL-38 gene polymorphisms in thyroid-associated ophthalmopathy.International ophthalmology · 2024Article
- Microglia-Dependent Reversal of Depression-Like Behaviors in Chronically Stressed Mice by Administration of a Specific Immuno-stimulant β-Glucan.Neurochemical research · 2024Article
- Lentinan progress in inflammatory diseases and tumor diseases.European journal of medical research · 2024Review
- Puerarin alleviates chronic renal failure-induced pyroptosis in renal tubular epithelial cells by targeting miR-342-3p/TGF-β/SMAD axis.Genes & genomics · 2023Article
- Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review.Antioxidants (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Demyelinating diseases such as multiple sclerosis (MS) are chronic inflammatory autoimmune diseases and involve demyelination and axonal degeneration. Microglia rapidly respond to changes in the environment by altering morphotype and function during the progressive disease stage. Although substantial progress has been made in the drug development for MS, treatment of the progressive forms of the disease remains unsatisfactory. There is great interest in identifying novel agents for treating MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.